Share on LinkedInShare on LinkedIn

ARTICLE · 20 FEBRUARY 2024

Petitioners Fail On Inherency But Prevail On Obviousness

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Petitioner, Celltrion, Inc., filed IPRs challenging each claim of U.S. Patent No. 8,580,264 ("the '264 patent") and U.S. Patent No. 10,874,677 ("the '677 patent") as anticipated...

United StatesIntellectual Property

Overview

Petitioner, Celltrion, Inc., filed IPRs challenging each claim of U.S. Patent No. 8,580,264 ("the '264 patent") and U.S. Patent No. 10,874,677 ("the '677 patent") as anticipated under 35 U.S.C. § 102 and obvious under 35 U.S.C. § 103. IPR2022-00578, Paper 78 at *6, IPR2002-00579, Paper 72 at *5.

The Patent Trial and Appeal Board ("the Board") found all claims of the challenged patents covering methods and devices for treating rheumatoid arthritis unpatentable.

The '264 Patent

Background

The '264 patent is directed to a method of treating rheumatoid arthritis (RA) with an anti-IL-6 receptor (IL-6R) antibody. IPR2022-00578, Paper 78 at *4. Claims 1, 10, and 12 are independent. Claims 1 and 10 recite, in relevant part:

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from